RMC No. 81-2021: VAT Exemption for FDA-Listed Medicines, COVID-19 Drugs, Vaccines, and Medical Devices Under CREATE

RMC No. 81-2021 identifies FDA-listed VAT-exempt medicines, COVID-19 drugs, vaccines, and medical devices under CREATE, with key dates. Businesses selling or importing qualifying medicines, COVID-19 treatment drugs and vaccines, and COVID-19 medical devices must treat covered items as VAT-exempt based on the FDA-endorsed list of VAT-exempt products under the CREATE Act. The practical effect is […]

RMC No. 101-2020: Addendum to VAT-Exempt Drugs for Hypertension, Diabetes and High Cholesterol

RMC No. 101-2020 publishes the FDA addendum to VAT-exempt drugs for hypertension, diabetes, and high cholesterol under RA 11467. Businesses selling, purchasing, prescribing, distributing, or accounting for medicines for hypertension, diabetes, and high cholesterol must immediately check whether their drug databases, point-of-sale systems, invoices, tax coding, and VAT treatment reflect the expanded list of VAT-exempt […]

RMO No. 23-2020: ATRIG Processing for VAT-Exempt Imported Prescription Drugs and Medicines

RMO No. 23-2020 centralizes ATRIG processing for VAT-exempt imported prescription drugs and medicines and confirms key exemption dates. Importers, manufacturers, distributors, wholesalers, and retailers dealing in VAT-exempt prescription drugs and medicines must secure the proper Authority to Release Imported Goods before release of covered importations. RMO No. 23-2020 centralizes the processing of ATRIG applications for […]